We sat down with Court Square Group for Season 2, Episode 12 of their series on life sciences investing and innovation, this time on the other side of the table: what it's like moving from funding life sciences AI companies to founding one.
Kalshi just launched biotech prediction markets as a pilot program, letting the public bet on outcomes like FDA approvals and clinical trial results. We think that's a serious mistake.
We analyzed 2M+ pharmaceutical payments to clinical sites and mapped them back to 10,000 clinical trials. The big takeaway: cost per site has been relatively stable since 2014, despite a massive increase in protocol complexity.
If we had a LinkedIn follower for every new AI-powered drug discovery company we come across... Last week, Anthropic revealed Claude Science, an AI workbench for scientists, setting off another round of discussion around frontier labs' role in the future of AI drug discovery.
This is a truly international summer, with the World Cup in full swing and the energy at DIA 2026 Annual Meeting, which brought together a global audience including top regulators from the FDA, UK's MHRA, and Japan's PMDA. These agencies shared interesting data across GCP inspections and spoke on the future of drug development.
At this point, no one is unfamiliar with the convenience of modern AI tools. We use it everywhere, outsourcing tedious tasks so that we're unlocked to do bigger, better things. The ROI is obvious, but the risks are not.
